Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)-Reference-Cited by-同舟云学术

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

Published:2018-07-31 Issue:9 Volume:9 Page:935-940
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Lagu Bharat¹^ORCID,Kluge Arthur F.¹,Tozzo Effie¹,Fredenburg Ross¹,Bell Eric L.¹,Goddeeris Matthew M.¹,Dwyer Peter¹,Basinski Andrew¹,Senaiar Ramesh S.²,Jaleel Mahaboobi²,Tiwari Nirbhay Kumar²,Panigrahi Sunil K.²,Krishnamurthy Narasimha Rao²,Takahashi Taisuke³,Patane Michael A.¹

Affiliation:

1. Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States

2. Aurigene Discovery Technologies, Ltd., Bengaluru and Hyderabad, India

3. Astellas Pharma., Tsukuba, Japan

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.8b00287

Reference20 articles.

1. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management